Real-world data showing a shift in preference towards NOACs and aspirin-free antiplatelet strategy

Real-world data showing a shift in preference towards NOACs and aspirin-free antiplatelet strategy

2020.11.02

A recent study investigating ‘real-world’ trends of antithrombotic treatment strategies in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI)...

Ticagrelor improves LV remodelling in post-PCI STEMI patients

Ticagrelor improves LV remodelling in post-PCI STEMI patients

2020.10.26

Ticagrelor showed superiority to clopidogrel for left ventricular (LV) remodelling after reperfusion of ST-segment elevation myocardial infarction (STEMI) with primary percutaneous coronary...

Modified HEART score effective as a predictive tool for MACE in Asian patients

Modified HEART score effective as a predictive tool for MACE in Asian patients

2020.10.19

Chest pain is the most common potentially life-threatening presentation to the emergency department (ED). Additionally, the diagnosis of acute coronary syndrome including its risk stratification and...

Higher WBC counts linked to worse clinical outcomes among post-PCI patients receiving ticagrelor monotherapy

Higher WBC counts linked to worse clinical outcomes among post-PCI patients receiving ticagrelor monotherapy

2020.10.12

Increased white blood cell (WBC) counts, which may reflect degree of inflammation, at the time of index procedure may attenuate the anti-ischaemic effects of ticagrelor monotherapy observed in...

Early DES-ISR and left ventricular systolic dysfunction associated with MACE

Early DES-ISR and left ventricular systolic dysfunction associated with MACE

2020.10.05

The mechanism and characteristics of early and late drug-eluting stent in-stent restenosis (DES-ISR) have not been fully defined. Particularly, it remains unclear whether outcomes among these...

Diabetes impacts worse prognosis in post-MI patients treated with PCI and antithrombotics

Diabetes impacts worse prognosis in post-MI patients treated with PCI and antithrombotics

2020.09.28

In an effort to evaluate the prognostic significance of diabetes mellitus (DM) in patients with high-risk acute myocardial infarction (MI) receiving primary percutaneous coronary intervention (pPCI)...

PD and PK study of ticagrelor loading dose in Chinese ACS patients

PD and PK study of ticagrelor loading dose in Chinese ACS patients

2020.09.25

The pharmacodynamics (PD) and pharmacokinetics (PK) of ticagrelor loading dose (LD) in Chinese patients with acute coronary syndrome (ACS) without opioid administration have not been investigated....

Secondary prevention combination therapy with beta-blocker and statin reduced MACE in ACS patients

Secondary prevention combination therapy with beta-blocker and statin reduced MACE in ACS patients

2020.09.21

A combination therapy of beta-blocker and statin more effectively lowered the risk of developing major adverse cardiovascular event (MACE) in patients with acute coronary syndrome (ACS), compared...

Implications of risk stratification for cholesterol management in ACS secondary prevention

Implications of risk stratification for cholesterol management in ACS secondary prevention

2020.09.18

In the 2018 American College of Cardiology/American Heart Association cholesterol guidelines for secondary prevention, patients are classified as ‘very high risk’ (VHR), either because of...

Ticagrelor showed benefits in post-MI stroke prevention among East Asian patients: A nationwide cohort study

Ticagrelor showed benefits in post-MI stroke prevention among East Asian patients: A nationwide cohort study

2020.09.14

Ticagrelor improves clinical outcomes in patients with acute myocardial infarction (AMI). A study was conducted to compare the efficacy and safety of ticagrelor versus clopidogrel in East Asian...